Objectives. Psoriatic arthritis (PsA) is an inflammatory joint disease, in which early neovascularization of affected skin and synovial tissue represents an important pathogenetic step in the disease process. Activation of the peroxisome proliferator activated receptor c (PPARc) showed anti-inflammatory effects in several in vitro and in vivo models (e.g. collagen-induced arthritis) by inhibition of angiogenesis and suppression of proinflammatory cytokines. Therefore, we studied the use of pioglitazone, a PPARc agonist originally developed for the treatment of diabetes, in patients with PsA. Methods. Ten patients with active PsA, seven males and three females, who showed at least two tender and two swollen joints despite stable treatment with an NSAID, were enrolled in this open-label study. All patients received a daily dose of 60 mg pioglitazone while continuing their current NSAID therapy. The primary endpoint was the PsARC (Psoriatic Arthritis Response Criterion); the secondary endpoints included the ACR20 response and improvement in the Psoriasis Area and Severity Index (PASI) in patients with more than 2% skin involvement. Patients were evaluated for endpoints at baseline and after 12 weeks. Results. After 12 weeks, six of 10 patients met the PsARC. The ACR20 response was achieved in five patients. The mean percentage reduction in PASI was 38%, with a clinically meaningful PASI 50 response in two of six patients. Median tender joint count (interquartile range) decreased from 12.0 (8.0-18.0) to 4.0 (2.0-10.0), and the median swollen joint count from 5.0 (4.0-8.0) to 2.0 (1.0-7.0) (P<0.05 for both). Median Health Assessment Questionnaire score changed from 1.0 (0.375-1.375) to 0.75 (0.375-1.0) (P<0.05). Three patients had to be withdrawn from the study due to inefficacy and side-effects. Major sideeffects were oedema of the lower extremities and increase in weight. Conclusions. Treatment with a PPARc agonist appears to be a promising therapeutic principle in PsA, but the use of PPARc ligands might be limited by side-effects such as increase in weight and fluid retention.
Psoriatic arthritis (PsA) is a chronic disorder characterized by inflammatory joint and skin disease. At present, the main options for treatment are the use of non-steroidal antiinflammatory drugs (NSAIDs) and different disease-modifying anti-rheumatic drugs (DMARDs) derived from clinical experience in the treatment of rheumatoid arthritis (RA). A few randomized and controlled studies have been undertaken to assess the effect of DMARDs in PsA, but they have shown inconsistent and unsatisfactory efficacy [1] [2] [3] [4] . In contrast, TNF-blocking agents have shown striking effectiveness in ameliorating skin and joint disease [5] , but their extensive use is limited due to high costs and potential side-effects, such as infections and demyelinating disease. Therefore, especially in mild to moderate PsA, novel therapies are warranted.
Thiazolidinediones are a novel class of insulin-sensitizing drugs developed for the treatment of diabetes mellitus type II. They act as ligands for the peroxisome proliferator-activated receptor (PPAR), a member of the nuclear hormone receptor superfamily of transcription factors. PPAR is expressed in a broad array of human tissues. Beyond its role in adipocyte differentiation, several recent reports support the idea that PPAR participates in the control of angiogenesis and inflammation (for review see [6, 7] ). Notably, PPAR activation by thiazolidinediones can significantly attenuate proinflammatory cytokine expression and suppress neoangiogenesis in different models of inflammatory disease [8] [9] [10] .
Angiogenesis has been identified as a distinctive pathological feature of psoriatic joint and skin disease [11] [12] [13] . Neoangiogenesis seems to appear at a very early stage of disease, since neovascularization in areas of clinically uninvolved skin precedes the onset of psoriatic plaques in these places [14] . Evidence is accumulating that agents designed to inhibit angiogenesis may also inhibit chronic inflammation, e.g. arthritis [15, 16] .
In the rat adjuvant arthritis model of human RA, treatment with the thiazolidinedione troglitazone resulted in significant improvement in paw swelling [17] . The clinical and histopathological signs of collagen-induced arthritis in mice could be ameliorated by rosiglitazone treatment [18] . Recently, a small trial of troglitazone treatment in patients with psoriasis also showed promising results [19] . Thus, in vitro and in vivo data suggest that PPAR ligands may have a beneficial therapeutic effect in psoriatic arthritis. Our study was designed to examine tolerability and parameters of disease activity during treatment with the PPAR agonist pioglitazone in patients with PsA.
Methods

Patients
Diagnosis of PsA was confirmed by a rheumatologist according to the following criteria: psoriatic skin disease and the presence of joint involvement matching the criteria of Moll and Wright Correspondence to: T. Bongartz. E-mail: bongartz.tim@mayo.edu [20] . Patients with a rheumatoid factor titre >1/80, an ANA titre>1:100 or anti-cyclic citrullinated peptide antibodies were excluded from the study.
Patients with active PsA, defined as having at least two painful and two swollen joints despite a minimum of 4 weeks of therapy with an NSAID prior to the initiation of study medication, were eligible for inclusion. During the entire study, NSAID therapy was maintained at a stable dose. Patients were excluded if they have been treated with disease-modifying drugs within the last 3 months.
Protocol
The protocol was approved by the local ethics committee of the University Hospital of Regensburg and all patients had to give written informed consent prior to entering the study. Throughout the study, patients were treated with 30 mg pioglitazone (Takeda Pharma, Aachen, Germany) twice daily and evaluated at week 0, 6 and 12 for response to therapy and for the occurrence of sideeffects. Patient assessment consisted of physical examination, measurements of disease activity (arthritis and psoriasis), concomitant medication and laboratory parameters (haematology, serum chemistry, urine analysis). Evaluation of disease activity included assessment of 78 joints (including iliosacral joints) for tenderness and 76 joints for swelling, patient's and physician's global health assessments (1-5 Likert scale), patient's assessment of pain [visual analogue scale (VAS)], patient's assessment of disability using the Health Assessment Questionnaire (HAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). In addition, patients with cutaneous manifestations of psoriasis affecting at least 2% of the body surface area were assessed for activity of skin disease.
Study endpoints
The primary endpoint addressing efficacy in PsA was the number of patients who met the Psoriatic Arthritis Response Criterion (PsARC, adapted from Clegg et al. [1] ) after 12 weeks of pioglitazone therapy. Meeting this response criterion requires improvement in two parameters (at least one being a joint score) and worsening in none of the following four parameters: patient's and physician's global assessments (improvement was defined as decrease of 1 unit and worsening as an increase of 1 unit) and tender and swollen joint scores (the sum of all joints scored; improvement was defined as a decrease of 30% and worsening as an increase of 30%).
The secondary endpoint for the assessment of PsA was the number of patients meeting the American College of Rheumatology preliminary criteria for improvement of RA (the ACR20 criterion) after 12 weeks [21] . This index requires a reduction of at least 20% in swollen and tender joint counts and a 20% reduction in at least three of the following criteria: patient's assessment of pain (VAS), patient's global assessment, physician's global assessment, ESR and health-associated quality of life.
In patients with cutaneous psoriasis affecting at least 2% of their body surface, the mean percentage decrease in the Psoriatic Area and Severity Index (PASI), was assessed as another secondary endpoint [22] . Clinically meaningful improvement was defined as a decrease of at least 50% in the PASI.
Statistical methods
Clinical parameters were compared between study entry and after 12 weeks by the Wilcoxon rank sum test. A P value <0.05 was regarded as statistically significant. All statistical analyses were done using SPSS software version 11.5 (Lead Technologies, Chicago, IL, USA)
Results
Baseline characteristics of the 10 patients enrolled in the study are summarized in Table 1 . The outcome measurements of the seven patients who completed the study are depicted in Table 2 . After 12 weeks, the median joint count decreased from 12.0 tender and 5.0 swollen joints to 4.0 and 2.0, respectively (P<0.05 for both). Although not significant, patient's median global assessment of disease activity decreased from 4.0 to 2.0 on the five-point Likert scale. In contrast, physician's median global assessment showed a significant reduction, from 3.0 to 2.0 (P<0.05). Patient's median assessment of disability according to the HAQ and median joint pain assessed by the patient on a 100 mm VAS dropped from 1.0 to 0.75 (P<0.05) and from 7.2 to 5.2 (P ¼ 0.063), respectively. ESR and CRP showed a decrease that was not statistically significant. Patients with psoriatic skin disease affecting >2% of body surface (n ¼ 6). *P-value < 0.05. 
Primary and secondary endpoints
Six patients achieved the primary endpoint criterion (PsARC) and five patients an ACR 20 response. Three patients had to be withdrawn from the study due to inefficacy and side-effects (see below). The mean percentage reduction in PASI was 38%, with a clinically meaningful PASI 50 response in two of the six patients. Of the three patients who had to be withdrawn from the study prematurely, two showed an increase in disease activity despite pioglitazone treatment: one patient with generalized erythematous psoriasis had to be withdrawn at week 2 due to an extension of his skin involvement and received systemic immunosuppressive therapy. A second patient with severe mutilating arthritis already refractory to methotrexate, sulphasalazine and cyclosporin treatment presented with a flare of his joint disease at week 8.
Adverse events
Six out of 10 patients participating in the study reported an adverse event. Three patients developed oedema of the lower extremities and a weight gain of more than 2 kg. One of these patients presented with an increase in weight of 14 kg at the final visit. Of interest, she suffered from obesity before the study and reported a massive increase in appetite throughout the study. As her oedema of the lower extremities was only mild, the increase in weight gain was attributed to an increase in body mass. Two patients had episodes of nervousness that lasted for 5-10 min and resolved spontaneously. Neither of them showed decreased blood glucose levels at the time of the visits. One patient had an asymptomatic increase in creatine kinase following an alcohol excess and enhanced physical exercise, which resolved despite continuation of study medication. No serious adverse event was observed.
One patient had to be withdrawn from the study prematurely because of severe oedema of the lower extremities, although this patient had responded clinically according to the PsARC prior to the onset of oedema.
Discussion
To our knowledge, this is the first study addressing the effects of a PPAR agonist as therapy for a rheumatic disease. Of the eight clinical and laboratory parameters used to evaluate the efficacy of pioglitazone in PsA over a period of 12 weeks, four improved significantly in the patients who completed the study: tender and swollen joint counts, physician's global assessment and patient's assessment of disability. The two objective parameters reflecting disease activity, ESR and CRP, did not show a statistically significant decrease. Since ESR and CRP were elevated in only three and six patients respectively at baseline (two of whom had to be withdrawn from the study prematurely), it is difficult to conclude whether there is a biological effect on inflammatory parameters. This would request a larger number of patients with raised values at baseline.
Six patients met the PsARC and five an ACR 20 response. Furthermore, an improvement of skin involvement was demonstrated by a mean decrease in PASI of 38%; a clinically meaningful improvement (PASI 50) was achieved in two patients. Owing to the open-label, single-arm design, it is not possible to confirm the general efficacy of PPAR treatment in psoriatic arthritis.
The pleiotropic function of PPAR activation raised some concerns about possible side-effects. Of these, liver toxicity in particular has been a rare but severe adverse event during troglitazone treatment and resulted in withdrawal of the drug in 2001 [23, 24] . None of our patients developed abnormal liver enzymes during therapy.
In the present study, increase in body weight and peripheral oedema were the major side-effects. Both of these side-effects have been reported in the diabetes studies with pioglitazone, rosiglitazone and troglitazone, suggesting a class effect of these drugs [25] [26] [27] [28] . It should be noted that the number of patients showing these side-effects in our study appears rather high compared with observations in the diabetes studies.
A possible explanation for this phenomenon might be the high dose of 60 mg pioglitazone/day, which exceeds the maximum dose used in diabetes by 15 mg. Another reason could be the comedication with NSAIDs, which can also cause fluid retention and might have amplified this side-effect [29] . In one patient, a significant elevation of the creatine kinase appeared after excessive alcohol consumption and physical exercise, and resolved quickly despite continuation of therapy.
The observation that major clinical improvement appeared between week 6 and week 12 suggests that patients may require at least 3 months to achieve a significant clinical response.
There are two major problems associated with the currently available in vitro and in vivo data addressing the mechanism of action by which PPAR ligands may exert their anti-inflammatory effects. First, these models differ substantially from human disease and the doses of thiazolidinediones used in these studies are at least 100-fold higher than those used for antidiabetic therapy in humans. Our study revealed that a dose exceeding 60 mg/day is limited due to the side-effects observed.
Secondly, there are indications that some of the antiinflammatory effects of thiazolidinediones are PPARindependent. Chawla et al. [30] were able to show in PPAR-null mice that thiazolidinediones exert anti-inflammatory effects independent of PPAR activation. In addition, despite the high affinity of thiazolidinediones for PPAR, their anti-inflammatory effects are weaker compared with those of the low-affinity ligand 15d-PGJ2 in different in vitro and in vivo models.
Further investigations should also focus on PPAR-independent anti-inflammatory mechanisms, leading to the development of drugs with a better risk/benefit ratio than thiazolidinediones in high doses.
In summary, since their discovery in the early 1990s, it has become clear that PPARs take part in the complex regulation of lipogenesis, glucose haemostasis and inflammation. The present study supports the hypothesis that patients with PsA may benefit from therapy with PPAR ligands. This needs to be evaluated in larger controlled trials.
